Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $138,910.58 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 12,946 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $10.73, for a total value of $138,910.58. Following the completion of the transaction, the executive vice president now owns 722,128 shares in the company, valued at $7,748,433.44. This trade represents a 1.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

David Sponsel also recently made the following trade(s):

• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The shares were sold at an average price of $11.42, for a total value of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The shares were sold at an average price of $10.00, for a total transaction of $2,380.00.

Alphatec Price Performance

Shares of Alphatec stock opened at $11.06 on Thursday. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -8.64 and a beta of 1.43. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $15.41. The firm’s 50-day moving average price is $10.57 and its two-hundred day moving average price is $8.35.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. On average, equities analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

ATEC has been the subject of a number of analyst reports. Needham & Company LLC boosted their price objective on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Tuesday, January 14th. Finally, Barclays boosted their price objective on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.56.

Institutional Trading of Alphatec

Several institutional investors and hedge funds have recently made changes to their positions in ATEC. Lido Advisors LLC grew its stake in shares of Alphatec by 8.4% during the fourth quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company’s stock worth $112,000 after purchasing an additional 953 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Alphatec by 0.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock valued at $2,873,000 after acquiring an additional 1,120 shares during the last quarter. Comerica Bank raised its position in shares of Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 1,248 shares during the period. Summit Investment Advisors Inc. boosted its stake in Alphatec by 14.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company’s stock worth $100,000 after acquiring an additional 1,342 shares during the last quarter. Finally, Atria Investments Inc increased its stake in Alphatec by 8.0% in the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after purchasing an additional 1,460 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.